MDWD: VALUE phase III trial and manufacturing expansion set the stage for growth in wound care
A validated enzymatic platform drives growth, with NexoBrid generating revenue and EscharEx in a pivotal phase III trial for chronic wounds. The main catalyst is the VALUE trial readout by Q1 2027, while manufacturing expansion and new indications are set to support future growth.Based on MediWound…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.